Literature DB >> 12810968

Surgical management of malignant soft tissue tumours in patients aged 65 years or older.

S Osaka1, H Sugita, E Osaka, Y Yoshida, J Ryu.   

Abstract

OBJECTIVE: With the aim to determine the most effective treatment for primary malignant musculoskeletal tumours in patients aged 65 years or older, we reviewed cases of low- and high-grade neoplasms, surgical margins, surgical methods, and the prognoses of elderly and aged patients at our institution.
METHODS: Records of 25 patients aged 65 years or older who had malignant soft tissue tumours from December 1986 to February 1997 were reviewed. Low- and high-grade neoplasms accounted for 8 and 17 patients, respectively. 11 patients were aged 65 to 69 years, while 14 were 70 years or older. Surgical margins were wide in 19 cases, marginal in 4, and intralesional in 2. Reconstruction was done using 6 musculocutaneous flaps and/or 4 vessel grafts. As adjuvant therapy, radiotherapy was used in 5 cases and chemotherapy in 3. There was no recurrence in patients with wide surgical margins (determined on the basis of gross inspection of the excised tumour and the cut surface); but there was recurrence in 4 patients with marginal margins, and one patient with intralesional margin. Two patients with intralesional, 4 with marginal, and 2 with wide margins, died from recurrence at the primary site and metastasis, or from metastasis without recurrence at the primary site.
RESULTS: Follow-up periods ranged from 4 months to 180 months (mean, 91.6 months). The overall 5-year survival rate was 79.6%; for low- and high-grade neoplasms, the figures were 100% and 69.7%, respectively; for those aged 65 to 69 years and in their 70's or older, the figures were 90.9% and 70.1%, respectively.
CONCLUSION: For geriatric patients, wide surgical margins are required to manage both low- and high-grade neoplasms, in order to avoid multiple surgeries.

Entities:  

Mesh:

Year:  2003        PMID: 12810968     DOI: 10.1177/230949900301100107

Source DB:  PubMed          Journal:  J Orthop Surg (Hong Kong)        ISSN: 1022-5536            Impact factor:   1.118


  7 in total

1.  What is the effect of advanced age and comorbidity on postoperative morbidity and mortality after musculoskeletal tumor surgery?

Authors:  Koichi Ogura; Hideo Yasunaga; Hiromasa Horiguchi; Kiyohide Fushimi; Hirotaka Kawano
Journal:  Clin Orthop Relat Res       Date:  2014-08-20       Impact factor: 4.176

2.  Prognostic factors for elderly patients with primary malignant bone and soft tissue tumors.

Authors:  Tadashi Iwai; Manabu Hoshi; Jun Takada; Naoto Oebisu; Masanari Aono; Masatsugu Takami; Makoto Ieguchi; Hiroaki Nakamura
Journal:  Oncol Lett       Date:  2015-06-29       Impact factor: 2.967

3.  The prognostic significance of surgical treatment for excessive elderly patients with soft tissue sarcoma.

Authors:  Hiroyuki Tsuchie; Makoto Emori; Hiroyuki Nagasawa; Naohisa Miyakoshi; Yasutaka Murahashi; Emi Mizushima; Toshihiko Yamashita; Yoichi Shimada
Journal:  Int J Clin Oncol       Date:  2018-02-27       Impact factor: 3.402

4.  Significance of local treatment in patients with metastatic soft tissue sarcoma.

Authors:  Long Jiang; Shanshan Jiang; Yongbin Lin; Dongrong Situ; Han Yang; Yuanfang Li; Hao Long; Zhiwei Zhou
Journal:  Am J Cancer Res       Date:  2015-05-15       Impact factor: 6.166

5.  The Significance of a "Close" Margin in Extremity Sarcoma: A Systematic Review.

Authors:  Ike Hasley; Yubo Gao; Amy E Blevins; Benjamin J Miller
Journal:  Iowa Orthop J       Date:  2018

6.  Comorbidity is independently associated with poor outcome in extremity soft tissue sarcoma.

Authors:  Seungcheol Kang; Han-Soo Kim; Wanlim Kim; Jun Ho Kim; So Hyun Kang; Ilkyu Han
Journal:  Clin Orthop Surg       Date:  2015-02-10

7.  Inflammatory Undifferentiated Pleomorphic Sarcoma Mimicking Bacteremia in an Elderly Patient: A Case Report.

Authors:  Kazuhiko Hashimoto; Shunji Nishimura; Tomohiko Ito; Naohiro Oka; Masao Akagi
Journal:  Medicina (Kaunas)       Date:  2021-02-18       Impact factor: 2.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.